CEO: Fredrik Tiberg
Investment area: Quality of life
Investment year: 1991
Website: www.camurus.com
Camurus develops and commercializes innovative, long-acting medicines for patients with severe and chronic diseases, such as addiction, pain, cancer, and endocrine disorders. Through its FluidCrystal® technology, medicines are released in a controlled manner in the body, providing long-lasting therapeutic effects. Camurus aims to create value for patients, healthcare providers, and society. Headquartered in Lund, Camurus operates across Europe, the US, and Australia. Its stock (CAMX) is listed on Nasdaq Stockholm.